MedTrace Logo

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

NCT04710134 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-01-25

No results posted yet for this study

Summary

Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.

Conditions

  • Asthma; Eosinophilic

Interventions

BIOLOGICAL

Reslizumab

Reslizumab 3,4, or 5 mg/kg IV q4 weeks

Sponsors & Collaborators

Principal Investigators

  • Parameswaran Nair, MD, PhD · McMaster University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2024-01-09
Completion
2024-01-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710134 on ClinicalTrials.gov